Immunohistochemical Study of IMP3 Expression in Laryngeal Squamous Cell Carcinoma
DOI:
https://doi.org/10.3889/oamjms.2021.6948Keywords:
IMP3, Laryngeal squamous cell carcinoma, list of vital and essential drugsAbstract
BACKGROUND: IMP3 is an RNA binding protein, which is strongly expressed in malignant tumors, promoting tumor cell proliferation.
AIM: The aim of the study was to evaluate the expression of IMP3 in laryngeal squamous cell carcinoma (SCC) and to correlate the expression of IMP3 with available clinicopathological data.
METHODS: Sixty one total laryngectomy and laryngoscopic biopsies; collected from the Pathology Department, Faculty of Medicine, Cairo University. Two slides were prepared from each paraffin embedded tumor block, one slide for Hematoxylin and Eosin staining, and the other for immunohistochemical staining by IMP3 polyclonal antibody.
RESULTS: Thirty-seven cases (60.7%) showed positive IMP3 expression, and a statistically significant correlation was found between IMP3 expressions in normal, dysplastic epithelium/in situ component, and the invasive malignant tumor tissue. Correlations between IMP3 expression and other available clinicopathological data were all non-significant.
CONCLUSION: This study suggests that IMP3 might play a role in laryngeal SCC carcinogenesis and progression process from normal to dysplastic to malignant epithelium, and thus IMP3 might be targeted by gene therapy.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. https://doi.org/10.3322/caac.20107 PMid:21296855 DOI: https://doi.org/10.3322/caac.20107
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. https://doi.org/10.3322/ caac.21332 DOI: https://doi.org/10.3322/caac.21332
Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M. Molecular markers in laryngeal squamous cell carcinoma: Towards an integrated clinicobiological approach. Eur J Cancer. 2005;41(5):683-93. https://doi.org/10.1016/j.ejca.2004.10.031 PMid:15763643 DOI: https://doi.org/10.1016/j.ejca.2004.10.031
Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer. 2005;5(2):127-35. https:// doi.org/10.1038/nrc1549 DOI: https://doi.org/10.1038/nrc1549
Koskinen WJ, Brøndbo K, Dahlstrand HM, Luostarinen T, Hakulinen T, Leivo I, Molijn A, Quint WG, Røysland T, Munck-Wikland E, Mäkitie AA. Alcohol, smoking and human papillomavirus in laryngeal carcinoma: A Nordic prospective multicenter study. Journal of cancer research and clinical oncology. 2007 Sep;133(9):673-8. https://doi.org/10.1007/s00432-007-0219-8 DOI: https://doi.org/10.1007/s00432-007-0219-8
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005 Mar;55(2):74- 108. https://doi.org/10.3322/canjclin.55.2.74 DOI: https://doi.org/10.3322/canjclin.55.2.74
Zhang SY, Lu ZM, Luo XN, Chen LS, Ge PJ, Song XH, Chen SH, Wu YL. Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment. PLoS One. 2013 Apr 4;8(4):e60157. https://doi.org/10.1371/journal.pone.0060157 DOI: https://doi.org/10.1371/journal.pone.0060157
Schorn VJ, Miles BA. Laryngeal squamous cell carcinoma. InENT Board Prep 2014 (pp. 227-233). Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8354-0_20 DOI: https://doi.org/10.1007/978-1-4614-8354-0_20
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. https://doi.org/10.1155/2014/437971 DOI: https://doi.org/10.1155/2014/437971
Chen X, Gao L, Sturgis EM, Liang Z, Zhu Y, Xia X, Zhu X, Li G, Gao Z. HPV16 DNA and integration in normal and malignant epithelium: Implications for the etiology of laryngeal squamous cell carcinoma. Annals of Oncology. 2017 May 1;28(5):1105-10. https://doi.org/10.1093/annonc/mdx027 DOI: https://doi.org/10.1093/annonc/mdx027
Maurya SS, Katiyar T, Dhawan A, Singh S, Jain SK, Pant MC, et al. Gene-environment interactions in determining differences in genetic susceptibility to cancer in subsites of the head and neck. Environ Mol Mutagen. 2015;56(3):313-21. https://doi.org/10.1002/em.21920 PMid:25399842 DOI: https://doi.org/10.1002/em.21920
Zauri M, Berridge G, Thézénas ML, Pugh KM, Goldin R, Kessler BM, et al. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature. 2015;524(7563):114-8. https://doi.org/10.1038/nature14948 DOI: https://doi.org/10.1038/nature14948
Rosai J, Ackerman LV. Surgical Pathology. London, New York: Edinburgh; 2004.
SEER. Surveillance, Epidemiology, and End Results, 18 Registeries, National Cancer Institute 2016. Available from: http://www.seer.cancer.gov. [Last accessed on 2021 May 26].
Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev. 2011;25(11):1159-72. https://doi.org/10.1101/gad.2042311 PMid:21576258 DOI: https://doi.org/10.1101/gad.2042311
Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70(15):2657-75. https://doi.org/10.1007/s00018-012-1186-z PMid:23069990 DOI: https://doi.org/10.1007/s00018-012-1186-z
Lederer M, Bley N, Schleifer C, Hüttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 2014;29:3-12. https://doi.org/10.1016/j.semcancer.2014.07.006 PMid:25068994 DOI: https://doi.org/10.1016/j.semcancer.2014.07.006
Wächter K, Köhn M, Stöhr N, Hüttelmaier S. Subcellular localization and RNP formation of IGF2BPs (IGF2 mRNA-binding proteins) is modulated by distinct RNA-binding domains. Biol Chem. 2013;394(8):1077-90. https://doi.org/10.1515/ hsz-2013-0111 PMid:23640942 DOI: https://doi.org/10.1515/hsz-2013-0111
Vargas TR, Boudoukha S, Simon A, Souidi M, Cuvellier S, Pinna G, et al. Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization. Oncogene. 2014;33(22):2866-75. https://doi.org/10.1038/onc.2013.252 PMid:23812426 DOI: https://doi.org/10.1038/onc.2013.252
Ismerim AB, Ferreira SV, Lessa AM, Pereira AS Jr, Gurgel CA, Coutinho-Camillo CM, et al. Insulin-like growth factor II messenger RNA-binding protein 3 in Salivary Gland tumors. Appl Immunohistochem Mol Morphol. 2016;24(6):422-6. https://doi.org/10.1097/pai.0000000000000205 PMid:26258757 DOI: https://doi.org/10.1097/PAI.0000000000000205
Natkunam Y, Vainer G, Chen J, Zhao S, Marinelli RJ, Hammer AS, et al. Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. Haematologica. 2007;92(2):176-83. https://doi.org/10.3324/haematol.10724 PMid:17296566 DOI: https://doi.org/10.3324/haematol.10724
Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathol. 2009;22(3):469-75. https://doi.org/10.1038/modpathol.2008.206 PMid:19136932 DOI: https://doi.org/10.1038/modpathol.2008.206
Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: Validation of the Turin proposal and analysis of IMP3 expression. Modern Pathol. 2010;23(9):1269-78. https://doi.org/10.1038/modpathol.2010.117 PMid:20562850 DOI: https://doi.org/10.1038/modpathol.2010.117
Lin CY, Chen ST, Jeng YM, Yeh CC, Chou HY, Deng YT, et al. Insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2011;40(9):699-705. https://doi.org/10.1111/j.1600-0714.2011.01019.x PMid:23647076 DOI: https://doi.org/10.1111/j.1600-0714.2011.01019.x
Hwang YS, Ahn SY, Moon S, Zheng Z, Cha IH, Kim J, et al. Insulin-like growth factor-II mRNA binding protein-3 and podoplanin expression are associated with bone invasion and prognosis in oral squamous cell carcinoma. Arch Oral Biol. 2016;69:25-32. https://doi.org/10.1016/j.archoralbio.2016.05.008 PMid:27232357 DOI: https://doi.org/10.1016/j.archoralbio.2016.05.008
Ueki A, Shimizu T, Masuda K, Yamaguchi SI, Ishikawa T, Sugihara E, et al. Up-regulation of Imp3 confers in vivo tumorigenicity on murine osteosarcoma cells. PLoS One. 2012;7(11):e50621. https://doi.org/10.1371/journal.pone.0050621 PMid:23226335 DOI: https://doi.org/10.1371/journal.pone.0050621
Samanta S, Pursell B, Mercurio AM. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem. 2013;288(18):12569-73. https://doi.org/10.1074/jbc.c112.442319 PMid:23539627 DOI: https://doi.org/10.1074/jbc.C112.442319
Fadare O, Liang SX, Crispens MA, Jones HW, Khabele D, Gwin K, et al. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: Assessment of frequency and significance. Hum Pathol. 2013;44(8):1508-15. https://doi.org/10.1016/j.humpath.2012.12.003 PMid:23465280 DOI: https://doi.org/10.1016/j.humpath.2012.12.003
Chen K, Cornejo KM, Ye W, Wu Q, Liang J, Jiang Z. Oncofetal protein IMP3: A new diagnostic biomarker for laryngeal carcinoma. Hum Pathol. 2013;44(10):2126-31. https://doi.org/10.1016/j.humpath.2013.04.002 PMid:23806529 DOI: https://doi.org/10.1016/j.humpath.2013.04.002
Soddu S, Di Felice E, Cabras S, Castellanos ME, Atzori L, Faa G, Pilloni L. IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: An immunohistochemical study. Eur J Histochem. 2013;57(1):e6. https://doi.org/10.4081/ejh.2013.e6 PMid:23549465 DOI: https://doi.org/10.4081/ejh.2013.e6
Kim HJ, Kim GE, Lee JS, Lee JH, Nam JH, Choi C. Insulin-like growth factor-II mRNA-binding protein 3 expression in effusion cytology: A marker for metastatic adenocarcinoma cells and a potential prognostic indicator in gastric adenocarcinoma. Acta Cytol. 2014;58(2):167-73. https://doi.org/10.1159/000357199 PMid:24457229 DOI: https://doi.org/10.1159/000357199
Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505(7482):212-7. https://doi.org/10.1038/nature12785 PMid:24305048 DOI: https://doi.org/10.1038/nature12785
Burdelski C, Jakani-Karimi N, Jacobsen F, Möller-Koop C, Minner S, Simon R, et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncol Reports. 2018;39(1):3-12. https://doi.org/10.3892/or.2017.6072 PMid:29115542 DOI: https://doi.org/10.3892/or.2017.6072
Jonas TJ, Daniel C, Francisco T, Karen HC. Malignant Tumors of the Larynx. Website: EMedicine; 2014. Available from: http://www.emedicine.medscape.com/article/848592- overview#showall. [Last accessed on 2021 May 26].
Bhargava S, Visvanathan A, Patil V, Kumar A, Kesari S, Das S, et al. IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65. Oncotarget 2017;8(25):40469. https://doi.org/10.18632/oncotarget.17118 PMid:28465487 DOI: https://doi.org/10.18632/oncotarget.17118
Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L, et al. Prognostic value of high IMP3 expression in solid tumors: A meta-analysis. Onco Targets Ther. 2017;10:2849-63. https://doi.org/10.2147/ott.s128810 PMid:28652767 DOI: https://doi.org/10.2147/OTT.S128810
Clauditz TS, Wang CJ, Gontarewicz A, Blessmann M, Tennstedt P, Borgmann K, et al. Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med. 2013;42(2):125-32. https://doi.org/10.1111/j.1600-0714.2012.01178.x PMid:22643116 DOI: https://doi.org/10.1111/j.1600-0714.2012.01178.x
Riener MO, Hoegel J, Iro H, Hartmann A, Agaimy A. IMP3 and p16 expression in squamous cell carcinoma of the head and neck: A comparative immunohistochemical analysis. Oncol Lett. 2017;14(2):1665-70. https://doi.org/10.3892/ol.2017.6352 PMid:28789393 DOI: https://doi.org/10.3892/ol.2017.6352
Lu L, Wang S, Zhu Q, Qu Y, Gu W, Ning Y, et al. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes. Pathol Res Pract. 2018;214(8):1087-94. https://doi.org/10.1016/j.prp.2018.05.026 PMid:29866423 DOI: https://doi.org/10.1016/j.prp.2018.05.026
Downloads
Published
How to Cite
License
Copyright (c) 2021 Wala’a Ahmad Al-Sayed Ashmawy, Ahmed Mahmoud Abd-Elaziz, Amira Mohamed Bassam, Heba Abdelmonem Ibrahim (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
